Gilead Sciences, Inc.
GILD
Market Cap$136.81B
Close$
Earnings Call Q1 2025
April 24, 2025 - AI Summary
Solid Financial Performance: Gilead Sciences reported a 4% year-over-year growth in its base business (excluding Veclury) for Q1 2025, driven primarily by a 6% increase in HIV sales. However, total product sales, including Veclury, saw a 1% annual decline due to fewer COVID-19 hospitalizations.
Product Pipeline and New Launches: Gilead anticipates an FDA decision on lenacapavir for PrEP by June 19, 2025, which has the potential to significantly boost HIV sales in the future. The company is well-positioned for up to nine potential HIV product launches by the end of 2033.
Challenges from Medicare Part D Redesign: The new Medicare Part D structure is expected to negatively impact Gilead's HIV sales by approximately $900 million in 2025. Consequently, the company expects flat HIV sales for the year but anticipates a return to growth in 2026 as these headwinds ease.
Exclusive for Stockcircle Pro members
Sign up
$246.54
124.2% upside
Current Fair Value
124.2% upsideUndervalued by 124.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $136.81 Billion |
|---|---|
| Enterprise Value | $128.88 Billion |
| Dividend Yield | $3.1 (3.53700672849609%) |
| Earnings per Share | $0.38 |
| Beta | 0.31 |
| Outstanding Shares | 1,246,000,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 22.97 |
|---|---|
| PEG | -17.47 |
| Price to Sales | 4.78 |
| Price to Book Ratio | 7.33 |
| Enterprise Value to Revenue | 4.48 |
| Enterprise Value to EBIT | 15.72 |
| Enterprise Value to Net Income | 21 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Gilead Sciences, Inc.
CEO: Daniel O'Day